A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

This study is open to children and young people aged 1 year or older who have been diagnosed with neuroblastoma that has come back after previous treatment, and was considered high-risk. To join, doctors must be able to see or measure the cancer using scans or other tests. Unfortunately, if the cancer is only found by looking at bone marrow samples, without other clear signs, then this study might not be suitable.

You also need to be well enough to take part. This means your body, including your blood, kidneys, and liver, needs to be working reasonably well. Doctors will do some tests to check these things. You should also be able to do some normal daily activities, even if you need help getting around. There will be specific medical checks to make sure your body can handle the treatments.

Finally, parents or guardians will need to give their full permission for their child to join the study, and that permission needs to be recorded properly.

If you join the BEACON2 study, you will be assigned to one of several treatment groups like choosing Arm A or Arm B, which involve a combination of medicines given over 12 cycles, each lasting three weeks. There are also other groups, like Arm C, which might involve a slightly different combination. These treatments are given as part of your regular hospital visits.

Throughout the study, you'll have regular check-ups, scans, and blood tests to see how you're responding to the treatment and to monitor for any side effects. Researchers will also collect extra samples, like blood or bone marrow, during your routine medical procedures. These extra samples help them understand the disease better. The treatment phase itself lasts for about 9 months (12 cycles x 3 weeks), but visits and check-ups will continue for up to five years after the treatment finishes to see how you are doing in the long term. The study plans to recruit patients for three years.